Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05227001 | A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza | PHASE1 | COMPLETED | 440 | — | — | Apr 28, 2022 | Aug 4, 2023 | Mar 20, 2026 | 24 | United States |
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self reported in electronic diaries.
As elicited by investigational site staff.
As elicited by investigational site staff.
As measured at the central laboratory
As measured at the central laboratory.
ECG abnormalities consistent with probable or possible myocarditis or pericarditis, as judged by a cardiologist
ECG abnormalities consistent with probable or possible myocarditis or pericarditis, as judged by a cardiologist
| Arm | Type | Description |
|---|---|---|
| PF-07852352 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07852352 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07852352 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836391 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836391 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836391 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836394 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836394 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836394 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836395 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836395 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836395 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836396 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836396 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836396 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07867246 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07867246 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07867246 Influenza saRNA, high dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Quadrivalent influenza vaccine (QIV) | ACTIVE_COMPARATOR | - |
| PF-07871987 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07871987 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07871987 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07914705 Influenza saRNA mid dose | EXPERIMENTAL | - |
| PF-07914705 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07915048 Influenza saRNA, high dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-07852352 Influenza saRNA 1 | BIOLOGICAL | Intramuscular injection |
| PF-07836391 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07836394 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07836395 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07836396 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07867246 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| Placebo | BIOLOGICAL | Intramuscular injection |
| Quadrivalent influenza vaccine (QIV) | BIOLOGICAL | Intramuscular injection |
| PF-07871987 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07914705 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07915048 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
Inclusion Criteria: * Male or female participants 18 to 49 years of age. * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history,...